Contributors: Ryan Wesley Brown and Victoria Hawekotte, JD'24, MBE'24
To learn more about Ryan and Tori, click here.

The peptide compounding landscape is undergoing a dramatic transformation. What began as a necessary response to drug shortages has evolved into a regulatory battleground, with the FDA cracking down on GLP-1 compounding while simultaneously signaling openness to expanding access for other peptides. For stakeholders - from telehealth companies to healthcare providers to patients - the tides are changing fast.1
The story begins with scarcity. GLP-1 receptor agonists, largely prescribed for type 2 diabetes and obesity, experienced significant drug shortages that placed semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (the active ingredient in Mounjaro and Zepbound) on FDA’s Drug Shortage List. This designation is significant because it allows lawful production of compounded drug products without separate FDA approval. Under Sections 503A and 503B of the federal Food, Drug and Cosmetic Act, drugs listed on FDA’s shortage list are not considered commercially available or “essentially copies of approved drugs,” allowing pharmacies and approved compounders to produce quantities of those compounded drug products. The shortage created a legal pathway for compounding GLP-1s.
The shortages for both semaglutide and tirzepatide have now resolved, removing the drug shortage exception. But the compounding didn’t stop. Demand for GLP-1s among patients and providers remains high, offset by limited insurance coverage (both private and public payers, including Medicaid, often exclude obesity treatment).2 This demand-coverage gap has driven patients and providers toward compounded alternatives. However, Section 503A prohibits compounding drugs that are “essentially a copy” of a “commercially available drug product,” and 503B prohibits compounding “essentially a copy of one or more approved drugs.” 3
FDA has responded to the continued compounding of GLP-1s with a multi-pronged enforcement campaign. As Commissioner Marty Makary stated, “Compounded drugs can be important for overcoming shortages or meeting unique patient needs - but compounders should not try to compound drugs in a way that circumvents FDA’s approval process.” 4
The agency’s actions include:
- Import controls: FDA established a “green list import alert” to stop GLP-1 active pharmaceutical ingredients with potential quality concerns from entering the U.S. supply chain, though compliant manufacturers are not affected.5
- Safety warnings: FDA has warned about adverse events from compounded versions of semaglutide and tirzepatide, including dosing errors. As of July 31, 2025, the agency received 605 adverse event reports from compounded semaglutide and 545 reports related to compounded tirzepatide.6
- “Research purposes” crackdown: Certain companies have labeled peptides “for research purposes” and “not for human consumption” while allegedly selling products to consumers for human use with dosing instructions. FDA has issued warning letters to companies using this tactic, citing violations of 21 U.S.C. 331(d) and 355(a).7
- False advertising enforcement: FDA isn’t limiting its focus to “research purposes only” language. The agency issued a warning letter to Hims and Hers alleging that claims about compounded semaglutide products were false and misleading. FDA took issue specifically with Him and Hers’ claim marketing a “[w]eekly injectable GLP-1 with the same active ingredient as Ozempic and Wegovy,” which FDA said improperly implied equivalence with approved products.8
While FDA tightens the screws on GLP-1 compounding, a parallel development suggests the agency may be moving in the opposite direction for other peptides. HHS Secretary Robert F. Kennedy has indicated that FDA may seek to remove certain peptides from the Category 2 designation of Bulk Substances.9 The Category 2 designation essentially prohibits compounding due to safety risk concerns.10 Removal would open the door for additional, lawful compounding of these substances.11
This direction is supported by FDA’s representations in litigation in the Northern District of Texas: “FDA has informed Plaintiffs that, by the end of February 2027, the agency expects to submit to the Office of the Federal Register for publication a final rule that addresses the placement of the four bulk drug substances at issue in this lawsuit on FDA’s Section 503A Bulks List regulation.” 12 The case has been administratively closed pending a joint status report by the earlier of 14 days after FDA’s final rule is published or March 14, 2027.
More concrete movement came on April 15, when FDA announced that its Pharmacy Compounding Advisory Committee (PCAC) will convene on July 23–24 to discuss adding the following bulk drug substances to the Category 1 list of permissible compounding:
- BPC-157 for Ulcerative Colitis;
- KPV for wound healing and inflammatory conditions;
- TB-500 for wound healing;
- MOTs-C for obesity and osteoporosis;
- Emideltide for opioid withdrawal, chronic insomnia, and narcolepsy;
- Semax for cerebral ischemia, migraine, and trigeminal neuralgia; and
- Epitalon for insomnia.
Yet even as these doors may open, FDA has continued to issue warning letters to companies claiming to sell GLP-1s for “Research Use Only,” alerting these companies that their products are drugs and requiring corrective action. In short: GLP-1s face a crackdown while other peptides may get a green light.13
The landscape for peptide compounding is shifting rapidly - and in two directions at once. Stakeholders should monitor these developments closely.
- Compounders must ensure compliant compounding, particularly for GLP-1s, now that shortages have resolved;
- Providers and patients looking to potentially unlawfully compounded versions of GLP-1s should be aware of safety and effectiveness risks;
- Telehealth companies offering compounded drugs must be mindful of the FDA’s position on “research use only” language and monitor updates to the drug shortage list.
Contact Ryan at: [email protected]
Contact Tori at: [email protected]
REFERENCES
- FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s (Mar. 03, 2026), https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s.
- Elizabeth Williams, Medicaid Coverage of and Spending on GLP-1s (Jan. 16, 2026), https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s/.
- Guidance for Industry: Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act (Jan. 2018), https://www.fda.gov/media/98973/download?attachment; Guidance for Industry: Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act (Jan. 2018), https://www.fda.gov/media/98964/download.
- Note: FDA has stated that as of April 1, 2026, it “does not intend to take action against a compounder for compounding a drug product that is essentially a copy of a commercially available drug product regularly or in in ordinate amounts if the compounder fills four or fewer prescriptions of that compounded drug product during a calendar month.” FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize.
- https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss.
- Id.
- Id; See, e.g., Warning Letter to Xcel Research LLC, https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/xcel-research-llc-694608-12102024; Warning Letter to Summit Research Peptides, https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/summit-research-peptides-695607-12102024; Warning Letter to Synthetix Inc. DBA Helix Chemical Supply, https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/synthetix-inc-dba-helix-chemical-supply-668918-02072024.
- Warning Letter to Him & Hers, Inc. dba Hers, https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/hims-hers-health-inc-dba-hers-716825-09092025.
- Lauren Gardner, A Peptide in FDA’s Step, Politico: Prescription Pulse (Mar. 3, 2026).
- See Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Apr. 22, 2026), https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks.
- Id.
- Evexias Medical Centers, PLLC v. U.S. Food and Drug Administration, No. 4:24-cv-00293-O (N.D. Tx. Aug. 18, 2025), https://ecf.txnd.uscourts.gov/doc1/177117927034.
- Warning Letter to Gram Peptides (March 31, 2026), https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026; Warning Letter to Mile High Compounds LLC (Mar. 31, 2026), https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mile-high-compounds-llc-721600-03312026.